Am J Psychiatry 156:101-107, January 1999
©Copyright 1999 American Psychiatric Association
Fluoxetine Treatment for Depression in Patients With HIV and AIDS: A Randomized, Placebo-Controlled Trial
Judith G. Rabkin, Ph.D., M.P.H.,
Glenn J. Wagner, Ph.D., and
Richard Rabkin, M.D.
OBJECTIVE: The goals of this study were to determine whether fluoxetine is superior to placebo in treating HIV-seropositive patients with major depression or dysthymia or both, whether severity of immunosuppression is associated with treatment response, and whether fluoxetine treatment is associated with change in immune status as measured by CD4 cell count. METHOD: A double-blind, randomized, placebo-controlled 8-week trial of fluoxetine was conducted in a university-affiliated research outpatient clinic. The fluoxetine-placebo randomization was 2:1. All patients were offered 4 months of additional open treatment. Main outcome measures included the Clinical Global Impression, Hamilton Depression Rating Scale, and CD4 cell count. RESULTS: Of 120 patients randomly assigned to fluoxetine or placebo, 87 completed 8 weeks of treatment. In the total group, 51% had AIDS. All but three were men, 35% were nonwhite, and 6% had intravenous drug use as a risk factor. In an intention-to-treat analysis, 57% of fluoxetine patients and 41% of placebo patients were responders. Among patients who completed the study, 74% responded to fluoxetine and 47% to placebo; this difference was statistically significant. Severity of immunosuppression was not related to antidepressant response, attrition, or side effects, and fluoxetine treatment was not associated with change in CD4 cell count. CONCLUSIONS: Fluoxetine is an effective antidepressant in the context of HIV illness. However, both placebo response and attrition were substantial, suggesting both that nonspecific factors may be more salient and that yet another medication (i.e., an antidepressant) may be less acceptable among patients with serious medical illness already requiring multiple concomitant medications.
This article has been cited by other articles:
|
|
|
|
 
M. J. Repetto and J. M. Petitto
Psychopharmacology in HIV-Infected Patients
Psychosom Med,
June 1, 2008;
70(5):
585 - 592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ironson, C. O'Cleirigh, M. A. Fletcher, J. P. Laurenceau, E. Balbin, N. Klimas, N. Schneiderman, and G. Solomon
Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment
Psychosom Med,
November 1, 2005;
67(6):
1013 - 1021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Caballero and M. C Nahata
Use of Selective Serotonin-Reuptake Inhibitors in the Treatment of Depression in Adults with HIV
Ann. Pharmacother.,
January 1, 2005;
39(1):
141 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Currier, G. Molina, and M. Kato
Citalopram Treatment of Major Depressive Disorder in Hispanic HIV and AIDS Patients: A Prospective Study
Psychosomatics,
June 1, 2004;
45(3):
210 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Perlis, D. V. Iosifescu, J. Alpert, A. A. Nierenberg, J. F. Rosenbaum, and M. Fava
Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression
Psychosomatics,
June 1, 2004;
45(3):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Currier, G. Molina, and M. Kato
A Prospective Trial of Sustained-Release Bupropion for Depression in HIV-Seropositive and AIDS Patients
Psychosomatics,
April 1, 2003;
44(2):
120 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vitiello, M. A. Burnam, E. G. Bing, R. Beckman, and M. F. Shapiro
Use of Psychotropic Medications Among HIV-Infected Patients in the United States
Am J Psychiatry,
March 1, 2003;
160(3):
547 - 554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Barroso, J. S. Preisser, J. Leserman, B. N. Gaynes, R. N. Golden, and D. N. Evans
Predicting Fatigue and Depression in HIV-Positive Gay Men
Psychosomatics,
August 1, 2002;
43(4):
317 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Morrison, J. M. Petitto, T. T. Have, D. R. Gettes, M. S. Chiappini, A. L. Weber, P. Brinker-Spence, R. M. Bauer, S. D. Douglas, and D. L. Evans
Depressive and Anxiety Disorders in Women With HIV Infection
Am J Psychiatry,
May 1, 2002;
159(5):
789 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Psychiatric Aspects of HIV Care
AIDS Clinical Care,
November 1, 2001;
2001(1101):
6 - 6.
[Full Text]
|
|
|
|
|
|
|
J. R. Ickovics, M. E. Hamburger, D. Vlahov, E. E. Schoenbaum, P. Schuman, R. J. Boland, J. Moore, and for the HIV Epidemiology Research Study Group
Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study
JAMA,
March 21, 2001;
285(11):
1466 - 1474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. M. H. Strik, A. Honig, R. Lousberg, A. H. P. Lousberg, E. C. Cheriex, H. G. Tuynman-Qua, P. M. J. C. Kuijpers, H. J. J. Wellens, and H. M. Van Praag
Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Psychosom Med,
December 1, 2000;
62(6):
783 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Rabkin, G. J. Wagner, and R. Rabkin
A Double-blind, Placebo-Controlled Trial of Testosterone Therapy for HIV-Positive Men With Hypogonadal Symptoms
Arch Gen Psychiatry,
February 1, 2000;
57(2):
141 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
